NR1H4 and metabolic dysfunction-associated steatohepatitis: To study the effects of current investigational drugs on NASH lesion progression and regression, we treated the diet-induced NASH mice with Ocaliva (OCA), an agonist of FXR and a metabolic modulator, and Cenicriviroc (CVC), an inhibitor of CCR2/5 which is considered as an anti-inflammatory and fibrotic agent.